explore -WSS

explore

author：focus 2025-10-01 15:30:39 - browse：45165

Three Wegovy injection pens in a row — first opinion coverage from STAT — Adobe

Novo Nordisk will test whether its GLP-1 drugs can help people with alcohol-associated liver disease, and, as part of that, will study if the treatments will change the amount of alcohol people drink.

This appears to be the first time the company is getting involved in research to see if the booming class of GLP-1 diabetes and obesity drugs can affect substance consumption, a question that academic researchers have been probing but the pharmaceutical industry has so far avoided.

The nine-month study will try three drugs alone and in combinations against placebo. The primary outcome being tested is change in liver scarring, or fibrosis, and one of the secondary outcomes is changes in alcohol consumption. The news of the study was first reported by Bloomberg.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Medicare proceeds with plan to claw back hospital funds

WSS

Citing H5N1 threat, CDC urges peak flu monitoring this summer

H5N1 virus can be tracked in retail milk, scientists say

Digital health: a case of mistaken identity

Explaining an after

After Sarepta trial failure, Duchenne families brace for more debate

Listen: A conversation with researcher Kevin Esvelt on biosecurity

entertainment

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Wikipedia

Medicare details structure of new drug price negotiation program

For longer

Walensky prepares to leave CDC — and Congress — behind

Kidney transplant patients stopped immunosuppressants in trial

Heart attack and stroke risk calculators need revising

Listen: More tumult at BIO & coercive care for sickle cell patients

George Santos makes 1st court appearance after pleading not guilty to 13 counts

DeepMind touts AlphaFold's new skills as protein folding AI models face off

Guidelines to prevent youth baseball injuries need more muscle

Medicare proceeds with plan to claw back hospital funds

explore

Kidney transplant patients stopped immunosuppressants in trial

Kidney transplant patients stopped immunosuppressants in trial

ASCO eve: Let’s set the table for this year's meeting

Study finds gene variants tied to breast cancer risk in Black women

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

Readout Newsletter: Eli Lilly, AstraZeneca, Bristol Meyers Squibb

entertainment

focus

hotspot

focus